Frequency of Pseudomonas in Community-Acquired Pneumonia
DOI:
https://doi.org/10.70749/ijbr.v3i4.1040Keywords:
Community-acquired Pneumonia, Pseudomonas AeruginosaAbstract
Background: An emerging infection in CAP with important clinical ramifications is Pseudomonas aeruginosa. Optimizing treatment requires knowledge of its prevalence, risk factors, and antibiotic resistance. Objective: to ascertain P. aeruginosa prevalence in CAP, evaluate related risk variables, and measure how it affects clinical results. Methods: A qualitative study involving 120 randomly chosen CAP patients were carried out at a Quetta tertiary care hospital. Clinical features were examined when P. aeruginosa was discovered by microbiological testing. Results: In 12.5% of CAP patients, P. aeruginosa was found. These individuals were more likely to die, have longer hospital stays, and be admitted to the intensive care unit. Multiple antibiotic resistance was noted. Conclusion: This study highlights the significant impact of Pseudomonas aeruginosa on the prognosis of patients with community-acquired pneumonia (CAP), particularly concerning hospitalization rates and mortality. Early identification through microbiological testing and assessment of risk factors plays a crucial role in improving outcomes. Given the organism’s known resistance patterns, a more targeted antibiotic therapy is essential, especially for high-risk individuals. In severe cases, combination therapy may be necessary, while empirical treatment should always align with local resistance trends. The implementation of proper antimicrobial stewardship programs is critical to prevent the emergence and spread of further resistance. Findings: These findings underscore the need for personalized and evidence-based treatment strategies and can contribute meaningfully to the formulation of effective CAP management protocols. In regions experiencing rising antibiotic resistance, these insights are especially valuable for guiding clinical decision-making and optimizing patient care in both outpatient and inpatient settings.
Downloads
References
Ewig, S., & Torres, A. (n.d.). Community-acquired pneumonia: Staphylococcus aureus. Community-Acquired Pneumonia, 475-485. https://doi.org/10.1007/0-306-46834-4_29
Arancibia, F., Bauer, T. T., Ewig, S., Mensa, J., Gonzalez, J., Niederman, M. S., & Torres, A. (2002). Community-acquired pneumonia due to Gram-negative bacteria and pseudomonas aeruginosa. Archives of Internal Medicine, 162(16), 1849. https://doi.org/10.1001/archinte.162.16.1849
Kang, C., Song, J., Oh, W. S., Ko, K. S., Chung, D. R., & Peck, K. R. (2008). Clinical outcomes and risk factors of community-acquired pneumonia caused by Gram-negative bacilli. European Journal of Clinical Microbiology & Infectious Diseases, 27(8), 657-661. https://doi.org/10.1007/s10096-008-0485-7
Blanquer, J., Blanquer, R., Borras, R., Nauffal, D., Morales, P., Menendez, R., Subias, I., Herrero, L., Redon, J., & Pascual, J. (1991). Aetiology of community acquired pneumonia in Valencia, Spain: A multicentre prospective study. Thorax, 46(7), 508-511. https://doi.org/10.1136/thx.46.7.508
Miyashita, N., Shimizu, H., Ouchi, K., Kawasaki, K., Kawai, Y., Obase, Y., ... & Oka, M. (2008). Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. Medical Science Monitor, 14(4), CR171-CR176.
Charles, P., Whitby, M., Fuller, A., Stirling, R., Wright, A., Korman, T., Holmes, P., Christiansen, K., Waterer, G., Pierce, R., Mayall, B., Armstrong, J., Catton, M., Nimmo, G., Johnson, B., Hooy, M., & Grayson, M. (2008). The etiology of community‐acquired pneumonia in Australia: Why penicillin plus Doxycycline or a macrolide is the most appropriate therapy. Clinical Infectious Diseases, 46(10), 1513-1521. https://doi.org/10.1086/586749
Lieberman, D., Schlaeffer, F., Boldur, I., Lieberman, D., Horowitz, S., Friedman, M. G., Leiononen, M., Horovitz, O., Manor, E., & Porath, A. (1996). Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients. Thorax, 51(2), 179-184. https://doi.org/10.1136/thx.51.2.179
Kollef, M. H., Shorr, A., Tabak, Y. P., Gupta, V., Liu, L. Z., & Johannes, R. (2005). Epidemiology and outcomes of health-care–associated pneumonia. Chest, 128(6), 3854-3862. https://doi.org/10.1378/chest.128.6.3854
Guay, D. R. (2006). Guidelines for the management of adults with health care-associated pneumonia: Implications for nursing facility residents. The Consultant Pharmacist, 21(9), 719-725. https://doi.org/10.4140/tcp.n.2006.719
Micek, S. T., Kollef, K. E., Reichley, R. M., Roubinian, N., & Kollef, M. H. (2007). Health care-associated pneumonia and community-acquired pneumonia: A single-center experience. Antimicrobial Agents and Chemotherapy, 51(10), 3568-3573. https://doi.org/10.1128/aac.00851-07
Shorr, A. F., Zilberberg, M. D., Micek, S. T., & Kollef, M. H. (2008). Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care–associated pneumonia. Archives of Internal Medicine, 168(20), 2205. https://doi.org/10.1001/archinte.168.20.2205
Shindo, Y., Sato, S., Maruyama, E., Ohashi, T., Ogawa, M., Hashimoto, N., Imaizumi, K., Sato, T., & Hasegawa, Y. (2009). Health-care-Associated pneumonia among hospitalized patients in a Japanese community hospital. Chest, 135(3), 633-640. https://doi.org/10.1378/chest.08-1357
Prina, E., Ranzani, O. T., & Torres, A. (2015). Community-acquired pneumonia. The Lancet, 386(9998), 1097-1108. https://doi.org/10.1016/s0140-6736(15)60733-4
World Health Organization. The Top 10 Causes of Death. www.who.int/news-room/fact-sheets/detail/ the-top-10-causes-of-death
Wunderink, R. G., & Waterer, G. W. (2014). Community-acquired pneumonia. New England Journal of Medicine, 370(6), 543-551. https://doi.org/10.1056/nejmcp1214869
Musher, D. M., & Thorner, A. R. (2014). Community-acquired pneumonia. New England Journal of Medicine, 371(17), 1619-1628. https://doi.org/10.1056/nejmra1312885
Jain, S, Self, W, H, & Wunderink, R, G, et al. (2015). Community-acquired pneumonia requiring hospitalization among U. S. adults. N Engl J Med, 373, 415–427. https://doi.org/10.1056/nejmc1511751
Sibila, O., Rodrigo-Troyano, A., Shindo, Y., Aliberti, S., & Restrepo, M. I. (2016). Multidrug-resistant pathogens in patients with pneumonia coming from the community. Current Opinion in Pulmonary Medicine, 22(3), 219-226. https://doi.org/10.1097/mcp.0000000000000263
Palacio, F., Reyes, L. F., Levine, D. J., Sanchez, J. F., Angel, L. F., Fernandez, J. F., Levine, S. M., Rello, J., Abedi, A., & Restrepo, M. I. (2015). Understanding the concept of health care-associated pneumonia in lung transplant recipients. Chest, 148(2), 516-522. https://doi.org/10.1378/chest.14-1948
Polverino, E., Torres, A., Menendez, R., Cillóniz, C., Valles, J. M., Capelastegui, A., Marcos, M. A., Alfageme, I., Zalacain, R., Almirall, J., Molinos, L., Bello, S., Rodríguez, F., Blanquer, J., Dorado, A., Llevat, N., & Rello, J. (2013). Microbial aetiology of healthcare associated pneumonia in Spain: A prospective, multicentre, case–control study. Thorax, 68(11), 1007-1014. https://doi.org/10.1136/thoraxjnl-2013-203828
Sibila, O., Restrepo, M. I., & Anzueto, A. (2013). What is the best antimicrobial treatment for severe community-acquired pneumonia (Including the role of steroids and statins and other immunomodulatory agents). Infectious Disease Clinics of North America, 27(1), 133-147. https://doi.org/10.1016/j.idc.2012.11.014
Yin, Y., & Wunderink, R. (2016). Antibiotic resistance in community-acquired pneumonia pathogens. Seminars in Respiratory and Critical Care Medicine, 37(06), 829-838. https://doi.org/10.1055/s-0036-1593753
Chalmers, J. D., Reyes, L. F., Aliberti, S., & Restrepo, M. I. (2016). Empirical coverage of methicillin-resistantstaphylococcus aureusin community-acquired pneumonia: Those who do not remember the past are doomed to repeat it. Clinical Infectious Diseases, 63(8), 1145-1146. https://doi.org/10.1093/cid/ciw464
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009). Antibacterial-resistantpseudomonas aeruginosa: Clinical impact and complex regulation of Chromosomally encoded resistance mechanisms. Clinical Microbiology Reviews, 22(4), 582-610. https://doi.org/10.1128/cmr.00040-09
Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., Dowell, S. F., File, T. M., Musher, D. M., Niederman, M. S., Torres, A., & Whitney, C. G. (2007). Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases, 44(Supplement_2), S27-S72. https://doi.org/10.1086/511159
Brito, V., & Niederman, M. S. (2009). Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Current Opinion in Infectious Diseases, 22(3), 316-325. https://doi.org/10.1097/qco.0b013e328329fa4e
Kollef, M. H., Shorr, A., Tabak, Y. P., Gupta, V., Liu, L. Z., & Johannes, R. (2005). Epidemiology and outcomes of health-care–associated pneumonia. Chest, 128(6), 3854-3862. https://doi.org/10.1378/chest.128.6.3854
Restrepo, M., & Anzueto, A. (2009). The role of Gram-negative bacteria in healthcare-associated pneumonia. Seminars in Respiratory and Critical Care Medicine, 30(01), 061-066. https://doi.org/10.1055/s-0028-1119810
Arancibia, F., Bauer, T. T., Ewig, S., Mensa, J., Gonzalez, J., Niederman, M. S., & Torres, A. (2002). Community-acquired pneumonia due to Gram-negative bacteria and pseudomonas aeruginosa. Archives of Internal Medicine, 162(16), 1849. https://doi.org/10.1001/archinte.162.16.1849
Sibila, O., Laserna, E., Maselli, D. J., Fernandez, J. F., Mortensen, E. M., Anzueto, A., Waterer, G., & Restrepo, M. I. (2015). Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia. Respirology, 20(4), 660-666. https://doi.org/10.1111/resp.12506
Waterer, G. W. (2015). Healthcare‐associated pneumonia: Can we salvage anything from the wreckage? Respirology, 21(1), 8-9. https://doi.org/10.1111/resp.12695
Torres, A., Cillóniz, C., Ferrer, M., Gabarrús, A., Polverino, E., Villegas, S., Marco, F., Mensa, J., Menéndez, R., & Niederman, M. (2015). Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: Risk and prognosis. European Respiratory Journal, 45(5), 1353-1363. https://doi.org/10.1183/09031936.00152514
Ewig, S., Welte, T., Chastre, J., & Torres, A. (2010). Rethinking the concepts of community-acquired and health-care-associated pneumonia. The Lancet Infectious Diseases, 10(4), 279-287. https://doi.org/10.1016/s1473-3099(10)70032-3
Lopez, A., Amaro, R., & Polverino, E. (2012). Does health care associated pneumonia really exist? European Journal of Internal Medicine, 23(5), 407-411. https://doi.org/10.1016/j.ejim.2012.05.006
Restrepo, M. I., & Aliberti, S. (2013). Editorial commentary: Healthcare-associated pneumonia: Where do we go next? Clinical Infectious Diseases, 58(3), 340-341. https://doi.org/10.1093/cid/cit738
Chalmers, J. D., Rother, C., Salih, W., & Ewig, S. (2013). Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: A systematic review and meta-analysis. Clinical Infectious Diseases, 58(3), 330-339. https://doi.org/10.1093/cid/cit734
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., ... & Brozek, J. L. (2016). Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical infectious diseases, 63(5), e61-e111. https://doi.org/10.1093/cid/ciw353
Chalmers, J. D., Rother, C., Salih, W., & Ewig, S. (2013). Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: A systematic review and meta-analysis. Clinical Infectious Diseases, 58(3), 330-339. https://doi.org/10.1093/cid/cit734
Waterer, G. W. (2015). Healthcare‐associated pneumonia: Can we salvage anything from the wreckage? Respirology, 21(1), 8-9. https://doi.org/10.1111/resp.12695
Sibila, O., Laserna, E., Maselli, D. J., Fernandez, J. F., Mortensen, E. M., Anzueto, A., Waterer, G., & Restrepo, M. I. (2015). Risk factors and antibiotic therapy in Pseudomonas aeruginosa community-acquired pneumonia. Respirology, 20(4), 660-666. https://doi.org/10.1111/resp.12506
Torres, A., Cillóniz, C., Ferrer, M., Gabarrús, A., Polverino, E., Villegas, S., Marco, F., Mensa, J., Menéndez, R., & Niederman, M. (2015). Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: Risk and prognosis. European Respiratory Journal, 45(5), 1353-1363. https://doi.org/10.1183/09031936.00152514
Ewig, S., Welte, T., Chastre, J., & Torres, A. (2010). Rethinking the concepts of community-acquired and health-care-associated pneumonia. The Lancet Infectious Diseases, 10(4), 279-287. https://doi.org/10.1016/s1473-3099(10)70032-3
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., ... & Brozek, J. L. (2016). Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases, 63(5), 575-582. https://academic.oup.com/cid/article/63/5/575/2237827
Sibila, O., Rodrigo-Troyano, A., Shindo, Y., Aliberti, S., & Restrepo, M. I. (2016). Multidrug-resistant pathogens in patients with pneumonia coming from the community. Current Opinion in Pulmonary Medicine, 22(3), 219-226. https://doi.org/10.1097/mcp.0000000000000263
Yin, Y., & Wunderink, R. (2016). Antibiotic resistance in community-acquired pneumonia pathogens. Seminars in Respiratory and Critical Care Medicine, 37(06), 829-838. https://doi.org/10.1055/s-0036-1593753
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
